title: HLA-B2702 (77-83/83-77) peptide binds to beta-tubulin on human NK cells and blocks their cytotoxic capacity.
abstract: It has been described that peptides derived from a highly conserved region of the alpha1 helix of the first domain of HLA class I Ags exhibit immunomodulatory capacity blocking both T and NK cell cytotoxicity. In vivo treatment with these peptides prolongs survival of MHC-mismatched allografts. However, the molecular bases of these effects are still unclear. In this study, we further analyze the mechanisms by which the dimeric peptide HLA-B2702 (77-83/83-77) induces suppression of NK cell cytotoxicity. This peptide inhibits natural and redirected lysis mediated by NK cells without significantly affecting effector-target cell binding. We have also isolated and sequenced a protein that binds this inhibitory peptide, which structurally corresponds to beta-tubulin. Tubulin is the major protein of microtubules and is involved in target cell killing. Furthermore, B2702 peptide promotes GTP-independent tubulin assembly, producing aggregates that cannot be depolymerized by cold. Treatment of NK cells with Taxol or demecolcine, which interfere with microtubule organization, also prevents NK cell cytotoxicity. Taken together, these results support the hypothesis that the peptide B2702 (77-83/83-77) exerts its inhibitory effect on NK cell cytotoxicity by inducing polymerization of microtubules and interfering with their normal assembly/disassembly dynamics.
authors: Department of Immunology, Faculty of Medicine, Hospital Reina Sofía, University of Córdoba, Córdoba, Spain.
authors: R
authors: R
authors: Tarazona
authors: G
authors: G
authors: López-Lluch
authors: M D
authors: MD
authors: Galiani
authors: E
authors: E
authors: Aguado
authors: F
authors: F
authors: Barahona
authors: R
authors: R
authors: Solana
authors: J
authors: J
authors: Peña
mesh_terms: D000276:Adjuvants, Immunologic / Q000378:metabolism* / Q000494:pharmacology; D002461:Cell Line, Transformed; D003601:Cytotoxicity Tests, Immunologic; D003602:Cytotoxicity, Immunologic / Q000187:drug effects / Q000276:immunology*; D003703:Demecolcine / Q000494:pharmacology; D015796:HLA-B27 Antigen / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D020014:K562 Cells; D007694:Killer Cells, Natural / Q000276:immunology* / Q000378:metabolism*; D008024:Ligands; D008870:Microtubules / Q000378:metabolism; D008970:Molecular Weight; D017239:Paclitaxel / Q000494:pharmacology; D010446:Peptide Fragments / Q000276:immunology* / Q000378:metabolism* / Q000494:pharmacology; D011485:Protein Binding / Q000276:immunology; D020033:Protein Isoforms / Q000276:immunology / Q000378:metabolism; D014404:Tubulin / Q000276:immunology / Q000378:metabolism*; D014407:Tumor Cells, Cultured
chemical_list: D000276:Adjuvants, Immunologic; D015796:HLA-B27 Antigen; D008024:Ligands; D010446:Peptide Fragments; D020033:Protein Isoforms; D014404:Tubulin; C118185:decapeptide B 2702; D017239:Paclitaxel; D003703:Demecolcine